Theranos Investor Alert: Kessler Topaz Meltzer & Check, LLP Announces Update to Theranos, Inc. Investigation
RADNOR, Pa., April 14, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that it has expanded its investigation of Theranos, Inc. ("Theranos" or the "Company") on behalf of the Company's investors.
Theranos investors who wish to discuss this investigation and/or their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 – 7706 or at [email protected]. For additional information about the investigation, or to request information about this investigation online, please visit www.ktmc.com/theranos-inc.
On January 27, 2016, The Wall Street Journal reported that "federal inspectors found 'deficient practices' at a Theranos Inc. laboratory that 'pose immediate jeopardy to patient health and safety.'" The article further reported that a federal inspection had "uncovered five major infractions that violate the federal law governing clinical labs," and that one infraction was defined "as a situation 'likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.'"
On March 8, 2016, The Wall Street Journal reported that a "federal inspection report said a Theranos Inc. laboratory ran an important blood test on 81 patients in a six-month period despite erratic results from quality-control checks meant to ensure the test's accuracy," and that "[i]nnacurate results from the test can be especially serious for patients." Additionally, the report found "that the lab's director didn't have responsibility for the lab's quality control program and the lab's quality-control manager was unqualified."
Most recently, on April 13, 2016, The Wall Street Journal reported that "federal health regulators have proposed banning Theranos Inc. founder Elizabeth Holmes from the blood-testing business for at least two years after concluding that the company failed to fix what regulators have called major problems at its laboratory in California." Among other things, the regulators "found that Theranos failed to adequately correct 43 of 45 deficiencies identified by inspectors last year."
Theranos investors who wish to discuss this investigation and/or their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 – 7706 or at [email protected]. For additional information about the investigation, or to request information about this investigation online, please visit www.ktmc.com/theranos-inc.
Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
D. Seamus Kaskela, Esq.
Adrienne O. Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299 - 7706
(610) 667 - 7706
[email protected]
SOURCE Kessler Topaz Meltzer & Check, LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article